Status:

COMPLETED

Patient Selection for Hypoxia Modifying Treatments in Larynx Carcinomas

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

Dutch Cancer Society

Conditions:

Larynx Cancer

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to identify in a prospective manner microregional profiles of oxygenation and proliferation based on exogenous and endogenous markers that are predictive for outcome of ra...

Detailed Description

Purpose Prognostic indicators discriminate patients with good and bad prognosis. Predictive assays are tools that select patients for specific treatments or treatment modifications such that outcome ...

Eligibility Criteria

Inclusion

  • Pathological confirmed squamous cell carcinoma of the larynx.
  • TNM-classification (UICC 1997, appendix I):
  • T3-4 glottic or supraglottic carcinoma
  • T2 glottic carcinoma with impaired cord mobility or subglottic extension
  • T2 supraglottic carcinoma with invasion of mucosa of base of tongue or vallecula or invasion of the medial wall of the piriform sinus.
  • any N-stage, M0.
  • WHO performance status 0 or 1.
  • Age \> 18 years.
  • Written informed consent.
  • Treatment in the ARCON phase III trial

Exclusion

  • Prior or concurrent treatment for this tumour.
  • Severe stridor and adequate debulking of airway not possible.
  • Impaired renal function: serum creatinine above upper normal limit.
  • Use of nephrotoxic medication (including ACE-inhibitors) that cannot be discontinued for the duration of the radiation treatment.
  • Impaired hepatic function: ASAT and ALAT more than 1.5 times the upper normal limit.
  • Use of anti-convulsants that cannot be discontinued for the duration of the radiation treatment.
  • History of malignancy during the previous 5 years except basal cell carcinoma of skin, carcinoma in situ of the cervix, or superficial bladder neoplasm (pTa).

Key Trial Info

Start Date :

July 1 2001

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 1 2013

Estimated Enrollment :

79 Patients enrolled

Trial Details

Trial ID

NCT00160095

Start Date

July 1 2001

End Date

March 1 2013

Last Update

May 7 2015

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Free University Medical Centre Amsterdam

Amsterdam, Netherlands, po 7057 1007 MB

2

Rijnstate Ziekenhuis Arnhem

Arnhem, Netherlands, po 9555 6800 TA

3

Academic Hospital Maastricht

Maastricht, Netherlands, po 5800 6202 AZ

4

Radboud University Nijmegen Medical Centre

Nijmegen, Netherlands, 6500 HB